NAM
NBIX icon

Nissay Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Nissay Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Sell
12,463
-132
-1% -$19.6K 0.01% 529
2026
Q1 		$1.66M Buy
12,595
+203
+2% +$26.9K 0.01% 529
2025
Q4 		$1.76M Buy
12,392
+76
+0.6% +$11K 0.01% 532
2025
Q3 		$1.73M Buy
12,316
+66
+0.5% +$8.94K 0.01% 525
2025
Q2 		$1.54M Sell
12,250
-43
-0.3% -$4.93K 0.01% 556
2025
Q1 		$1.36M Buy
12,293
+107
+0.9% +$13.6K 0.01% 582
2024
Q4 		$1.7M Buy
12,186
+146
+1% +$18.1K 0.01% 560
2024
Q3 		$1.39M Buy
12,040
+466
+4% +$63.9K 0.01% 598
2024
Q2 		$1.59M Buy
11,574
+401
+4% +$55K 0.01% 553
2024
Q1 		$1.54M Buy
11,173
+233
+2% +$31.8K 0.01% 563
2023
Q4 		$1.44M Buy
10,940
+354
+3% +$40.7K 0.01% 549
2023
Q3 		$1.19M Buy
10,586
+354
+3% +$37.3K 0.01% 569
2023
Q2 		$965K Sell
10,232
-191
-2% -$18.7K 0.01% 615
2023
Q1 		$1.06M Sell
10,423
-402
-4% -$41.8K 0.01% 595
2022
Q4 		$1.29M Sell
10,825
-237
-2% -$27.8K 0.01% 538
2022
Q3 		$1.18M Buy
11,062
+431
+4% +$43.7K 0.01% 549
2022
Q2 		$1.04M Sell
10,631
-130
-1% -$12K 0.01% 578
2022
Q1 		$1.01M Buy
10,761
+265
+3% +$22.5K 0.01% 609
2021
Q4 		$894K Buy
10,496
+419
+4% +$38.5K 0.01% 663
2021
Q3 		$966K Buy
10,077
+409
+4% +$38.6K 0.01% 627
2021
Q2 		$941K Buy
9,668
+440
+5% +$42.2K 0.01% 644
2021
Q1 		$897K Sell
9,228
-222
-2% -$23.3K 0.01% 628
2020
Q4 		$906K Buy
9,450
+358
+4% +$34.6K 0.01% 608
2020
Q3 		$874K Buy
9,092
+237
+3% +$27.4K 0.01% 573
2020
Q2 		$1.08M Buy
8,855
+1,159
+15% +$128K 0.02% 499
2020
Q1 		$666K Buy
7,696
+318
+4% +$31.1K 0.02% 525
2019
Q4 		$793K Buy
+7,378
New +$772K 0.02% 587

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nissay Asset Management's NBIX Position: Q2 2026 in Review

Nissay Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 1% in Q2 2026, selling an estimated $19.6K and leaving 12,463 shares worth $2.1M. The position accounts for 0.01% of the portfolio, ranked #529.

Nissay Asset Management first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Nissay Asset Management held 12,463 shares of Neurocrine Biosciences worth $2.1M as of Q2 2026.
  • Nissay Asset Management sold 132 Neurocrine Biosciences shares in Q2 2026, an estimated $19.6K.
  • Neurocrine Biosciences made up 0.01% of Nissay Asset Management's portfolio in Q2 2026, its #529 holding.
  • Nissay Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Nissay Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.